developed ICH within 7 days of diagnosis of ITP; for 10 of these, ICH was the presenting feature of their ITP. Twelve children (30%) had chronic ITP. Head trauma and hematuria were the most prominent features associated with ICH, identified in 33% and 22.5% of the ICH cases and 1 and none of the controls (both P's <0.001). Bleeding beyond petechiae and ecchymoses was also linked to ICH. Mortality was 25%; a further 25% had neurological sequelae. Combinations of factors were tested as strategies by which high-risk children could be identified and the costs of combination treatment to prevent ICH in these cases were estimated. Children with severe thrombocytopenia plus head trauma and/or hematuria appeared to be at particularly high risk of ICH. Aggressive treatment of these children may be appropriate.
INTRODUCTION
Intracranial hemorrhage (ICH) is the most devastating complication of immune thrombocytopenic purpura (ITP) in children [1] and prevention of ICH is the primary goal of ITP treatment. However, the great majority of ITP patients, even those with very low platelet counts, do not experience severe bleeding [2] , and ICH occurs in less than 1 in 100 children with ITP [3] [4] [5] [6] . Existing case series are small, and reviews of published case reports may suffer from publication bias. The features that predispose patients to develop ICH in addition to severe thrombocytopenia remain poorly defined. Potential risk factors include platelet counts below 10-20 x 10 9 /L, non-steroidal anti-inflammatory drugs (NSAIDs), head trauma, vasculitis associated with systemic lupus erythematosis (SLE) and cerebral arteriovenous malformations (AVMs) [1, 3, [7] [8] [9] .
This study aimed to define the features associated with ICH in ITP. Information 
METHODS
A nationwide survey requested information on cases of ICH in patients with ITP aged < 17 years in the United States over the preceding 10 years (1987-1997) and yearly during a 4-year period from January 1997 to December 2000. ITP was defined according to the ASH guidelines [10] . The questionnaire was sent to members of the American Society of Pediatric Hematology and Oncology and selected members of the American Society of Hematology. Follow-up phone calls were made. Whenever possible, redacted chart copies were obtained. Hospital, Patterson NJ. Acute ITP was defined as < 6 months duration as the study was conducted prior to the new terminology [11] . Only children with primary ITP were included; cases of ICH in patients with secondary ITP are described in supplementary table 1. ICH was verified by CT in all but one case. IRB approval was obtained at Weill Cornell to acquire patient information without specific identifiers and therefore without consent.
Data was analyzed using means, medians, ranges, 2-tailed Fisher Exact tests for 2x2 tables, sensitivity (true positives divided by true positives plus false negatives), specificity (true negatives divided by true negatives plus false positives), and positive and negative predictive values using GraphPad Prism software. For the cost utility analyses of treatment strategies, the 10 children who had an ICH as the presenting feature of their ITP were excluded, as these cases were deemed not preventable.
RESULTS

Study patients
One hundred and twenty children with primary ITP were included, 40 with ICH and 80 as controls with platelet counts < 30 x 10 9 /L ( There were no differences in age, sex, or duration of ITP between the 40 ICH cases and the 80 case controls (Table 1) .
Platelet counts
The median platelet count of the 40 ICH patients was 5 x 10 9 /L (range 1 to 61 x had an ICH between 1 week and 6 months from diagnosis, and 12 patients (30%) had chronic ITP when their ICH occurred (Table 1) .
Risk Factors
Head trauma preceded ICH in 13 of 40 patients (33%) compared to only one control (P < 0.001).
Bleeding beyond skin petechiae and ecchymoses tended to be more frequent among the ICH cases than the case controls (63% vs. 44%, P = 0.08; NSAID's were recently used in 3 of 40 ICH cases (7%) and 1 control (NS, P = 0.1). No AVM's were identified.
Outcome
The ICH was lethal in 25% (10 of 40 cases, Table 2 ). Follow-up data was available in survivors for a median of 11 months (5 days to 6 years). Ten (33%) had neurological sequelae including: 4, hemiparesis; 4, facial weakness and/or cranial nerve palsy; 1, cognitive deficit; 1, epilepsy; 1, speech deficit; and 1, unavailable details.
Interrelationship of clinical variables
The 10 children whose ITP presented with ICH were more likely to have had head trauma than the other ICH cases (60% vs. 23%, P = 0.05). Young infants (3 years of age or younger) were more likely to have head trauma (P < 0.04, Figure 1a ) and more likely to have an ICH as the presenting feature of their ITP (P < 0.001, Figure 1b) . Compared to the 8 children who had an ICH in the first week following diagnosis, the 10 whose ITP presented with an ICH had a significantly lower incidence of bleeding beyond petechiae and ecchymoses (P = 0.02).
The 8 patients with an ICH in the first week following diagnosis of their ITP had significantly poorer outcomes than the other 32 patients. Only 1 made a full recovery: 38% had neurological sequelae and 50% died (P = 0.02). In contrast, 8 of the 10 patients (80%) who presented their ITP with an ICH survived without sequelae.
Mortality was higher in the patients who had bleeding beyond petechiae and ecchymoses (36% vs. 7%, P <0.01, Table 2 ) whereas it tended to be lower in cases with head trauma.
Treatments at any time prior to the ICH
Twenty-eight of the 40 ICH patients (70%) had received treatment for their thrombocytopenia: 16 of 28 (57%) of patients with acute ITP and 11 of 12 (92%) with
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Treatments after ICH
All 40 children received at least 1 treatment after the ICH: 78% received IVIG, 75% platelet transfusions, 73% corticosteroids, and 43% underwent splenectomy; 35% had a craniotomy. There was no difference in outcome between emergency splenectomy after ICH and medical management. In contrast, of the 14 who had a craniotomy, only 2 (14%) made a full recovery (P<0.001).
Combinations of risk factors and likelihood of ICH
Combining the risk factors head trauma and/or hematuria (Figure 2a) would have identified 21 of the 40 (53%) ICH cases. However, only 6 ICH patients (15%) had neither head trauma nor bleeding beyond skin petechiae and ecchymoses, as compared to 44 (55%) of the case controls (P < 0.001, Figure 2b) . Table 3 illustrates different algorithms that may be used to select high-risk patients.
DISCUSSION
This study accrued 40 cases of ICH in children with primary ITP in the United
States from 1987 to 2001; these children were compared to 80 matched controls.
Seventeen "retrospective" ICH cases that had occurred during the previous ten years were obtained in 1997, and 23 "prospective" cases were obtained through yearly surveys from
1997-2000.
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Are these data consistent with previous estimates of the incidence of ICH in children with ITP?
There are 70 million children in the USA [12] and it is estimated that the annual incidence of ITP is 5.5 children per 100,000 [5] . Therefore, approximately 3850 new cases of ITP are diagnosed annually. Six cases of ICH were reported per year on average during the 4-year "prospective" phase of the study. Accordingly, the yearly incidence of ICH in ITP could range from 7.5 (if 80% of all US ICH cases had been captured in this survey) to 30 (20% capture). Assuming that there are 3850 cases of ITP per year, the incidence of ICH in children with ITP in the USA would be 0.19-0.78%. This is consistent with previous estimates [1, 3, 5, 7, 13, 14] .
What distinguishes children with ITP who develop an ICH from those children with
ITP who do not?
Severe thrombocytopenia, head trauma, and hematuria were strongly and significantly associated with ICH.
Severe thrombocytopenia appears to be permissive but not sufficient for ICH. Bleeding symptoms beyond petechiae and bruises tended to occur more frequently in ICH cases than controls. Hematuria was reported in 9 ICH cases (microscopic in 3) but not in any controls (P < 0.001); the number of urinalyses in the control group is unknown [11, 15] . Gastrointestinal bleeding, epistaxis, gum bleeding and wet purpura were also more frequent in the ICH cases, but not significantly so (Table 1) .
Detailed information describing bleeding events e.g. duration of epistaxis was often unavailable.
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What is the outcome of patients with ITP-associated ICH?
The mortality rate was 25%, lower than reviews of published cases of ICH that may have been biased towards severe cases [3, 16] . A further 10 had neurological sequelae. Therefore, although the incidence of ICH is low, 50% of children died or had neurological disability. This is particularly striking given that ITP (without ICH) is typically a self-limited disease with no sequelae. The children who had an ICH in the first week after diagnosis of ITP seemed to do particularly poorly, possibly because children with severe hemorrhage may respond less well to treatment [1, 17] .
What are the implications for management of children with ITP?
Serious bleeding in children with ITP is quite infrequent both at diagnosis and later in the course [2, 18] . Considerable debate regarding management therefore remains, as attempts to prevent ICH must be balanced against treatment-related toxicities and cost implications in the many patients with very low counts but little bleeding [2, [19] [20] [21] [22] [23] [24] . In addition, ITP is typically a short-lived problem that may resolve in weeks to months. Conservative (i.e. non-interventional) management therefore appears appropriate for the majority of patients.
On the other hand, this survey suggests that it may be possible to identify highrisk cases prospectively [1, 2] , except when the ICH is the presenting feature of the ITP.
In cases of severe thrombocytopenia, head trauma and bleeding beyond petechiae and ecchymoses (especially hematuria) appear to predispose to ICH [1, 3, 15] . Other types of bleeding, such as wet purpura, gastrointestinal and vaginal, and the use of NSAIDs may also be important but were not as clearly related to ICH in this study.
For patients with a high likelihood of ICH, could it be prevented by timely therapy? We believe, as do others, that single agent therapy may often be ineffective in preventing ICH. We were unable to ascertain whether specific treatments may have prevented ICH in some cases in this series, had they been administered earlier or For personal use only. on October 3, 2017. by guest www.bloodjournal.org From repeatedly. Not only were details of response to therapies generally not available, but also response to therapy after ICH has occurred may not necessarily be indicative of response to therapy prior to or during ICH.
An option to consider, given the potential insufficiency of single agent treatment, is multiagent combination therapy using IVIG, high dose IV methylprednisolone with IV anti-D and/or IV vincristine [25] . In the Boruchov study, 10 children and 25 adults who were completely unresponsive to either steroids or IVIG given alone (median platelet count after initial treatment 8 x 10 9 /L) had a 71% response rate to combination therapy, achieving peak platelet counts > 30 x 10 9 /L. The cases reported by Boruchov, with severe thrombocytopenia and refractoriness to initial therapy, are comparable to the cases reported here in which ICH actually occurred.
Additional treatment needs to be considered early in patients with ITP at high risk for ICH who are not responding to standard therapy, especially in the first week following diagnosis of ITP. In dire cases, platelet transfusions (bolus followed by continuous infusion) or even recombinant human factor VIIa could be added.
Thrombopoietic agents might also have a role in combination therapy, although they generally require at least 5-8 days to increase the platelet count [26] .
The estimated treatment-related cost of preventing an ICH varies, depending upon the approach used to identify high-risk patients and the efficacy of combination therapy. Table 3 describes a preliminary consideration of selected strategies exploring prospective approaches to identifying children for treatment. The strategies ranged from 100% sensitivity (with only 23% specificity) to 99% specificity (with 50% sensitivity).
Although an oversimplification, the treatment cost per ICH prevented among the 3850 estimated base case 20kg children with ITP per year, ranged from $45,300 (50% sensitivity, 100% efficacy of treatment, and 99% specificity) to $3,400,000 (100% sensitivity, 50% efficacy and 23% specificity) ( Table 3) .
Other management considerations
The proportion of cases of ICH that occurred more than 6 months from diagnosis (29%) is substantial. Management of these patients is different, since the time horizon is potentially unlimited because spontaneous remission is no longer as likely. Treatment (e.g. danazol and azathioprin, rituximab, splenectomy, or thrombopoietic agents) [25] [26] [27] [28] [29] [30] [31] may need to be continued indefinitely for those whose persistent severe thrombocytopenia does not improve and who have ongoing risk factors for ICH, even if the platelet increment in response to treatment is small.
No specific medical treatment of ICH appeared to be associated with an improved neurological outcome. Emergency splenectomy was not associated with a better outcome and craniotomy was associated with a poorer outcome, suggesting that it may have been reserved for more severe cases.
Limitations
As with any survey study, details were limited especially in certain areas. For example, information on the efficacy of treatment was quite limited. Also, not all centers responded to the survey, although mail outs were sent yearly for 3 years and every listed center was called at least twice. Reporting biases are possible. An illustration of this is that petechiae were reported less frequently among the ICH cases than the controls, which seems counterintuitive. However, the higher mortality among the ICH patients who had more bleeding manifestations supports the accuracy of documentation of bleeding symptoms in the ICH cases. It is possible that the severity of the ICH influenced the likelihood of responding to the survey. Furthermore, a disproportionate number of the controls had to be taken from the Weill Cornell center because accompanying controls were not always provided by the physicians reporting the ICH cases. These and the other controls received treatment of their ITP as determined by their hematologists. In this survey study, investigation of the underlying pathophysiology of the ICH in patients with ICH was not possible. Finally, only a very preliminary analysis of strategies to identify and manage patients at high risk of ICH was performed and no formal cost-benefit analysis was conducted.
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Conclusion
There have been two schools of thought regarding management of markedly thrombocytopenic children with ITP. One is that given the rarity of ICH, therapy should almost always be avoided because in the majority of cases it is unnecessary as the ITP will spontaneously resolve and treatment may be toxic and ineffective. The other approach considers that although ICH is rare, it may be devastating, treatments are reasonably benign when used appropriately, and there are quality of life benefits to increasing the platelet count in addition to avoiding ICH. Both approaches, however, treat patients as if they all have equal risks of severe hemorrhage and neither provides a suitable approach to children with persistent, chronic, severe ITP. As is well-known, it is impossible to do a prospective, randomized study of treatment to prevent ICH in children with ITP [6] . This study argues that individual patients with ITP could be stratified according to their risk of impending ICH. Treatment or non-treatment could be decided accordingly. Given the possibility that single agents are not always effective, in high risk cases combination therapy may need to be considered [25] . 
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